Publication

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

CREDENCE Trial Investigators, Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., Cannon, C. P., Capuano, G., Chu, P. -L., De Zeeuw, D., Greene, T., Levin, A., Pollock, C., Wheeler, D. C., Yavin, Y., Zhang, H., Zinman, B., Meininger, G., Brenner, B. M. & Mahaffey, K. W., 13-Jun-2019, In : New England Journal of Medicine. 380, 24, p. 2295-2306 12 p.

Research output: Contribution to journalArticleAcademicpeer-review

Copy link to clipboard

Documents

  • Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

    Final publisher's version, 454 KB, PDF document

    Request copy

DOI

  • CREDENCE Trial Investigators
  • V. Perkovic
  • M. J. Jardine
  • B. Neal
  • S. Bompoint
  • H. J. L. Heerspink
  • D. M. Charytan
  • R. Edwards
  • R. Agarwal
  • G. Bakris
  • S. Bull
  • C. P. Cannon
  • G. Capuano
  • P. -L. Chu
  • D. De Zeeuw
  • T. Greene
  • A. Levin
  • C. Pollock
  • D. C. Wheeler
  • Y. Yavin
  • H. Zhang
  • B. Zinman
  • G. Meininger
  • B. M. Brenner
  • K. W. Mahaffey

Background Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium-glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients with type 2 diabetes. Methods In this double-blind, randomized trial, we assigned patients with type 2 diabetes and albuminuric chronic kidney disease to receive canagliflozin, an oral SGLT2 inhibitor, at a dose of 100 mg daily or placebo. All the patients had an estimated glomerular filtration rate (GFR) of 30 to 300 to 5000) and were treated with renin-angiotensin system blockade. The primary outcome was a composite of end-stage kidney disease (dialysis, transplantation, or a sustained estimated GFR of

Original languageEnglish
Pages (from-to)2295-2306
Number of pages12
JournalNew England Journal of Medicine
Volume380
Issue number24
Publication statusPublished - 13-Jun-2019

    Keywords

  • KIDNEY-DISEASE, EMPAGLIFLOZIN

View graph of relations

ID: 93747596